Securities fraud class action lawsuits against life sciences companies climbed 56 percent last year to 25 lawsuits filed, compared with 16 cases in 2006, according to a new Dechert survey.
The June 2008 Dechert “Survey of Securities Fraud Class Actions Brought Against Life Sciences Companies” also noted that the largest and smallest companies are the most likely to be sued, with large companies increasingly likely to face such lawsuits.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]